Answers are grounded in this paper and cite their sources.
Calcinosis affects 20% to 40% of patients with juvenile dermatomyositis (JDM), and is associated in particular with antinuclear matrix protein 2 (anti-NXP2) antibodies, younger age at disease onset, and persistent disease activity.1-3 Extensive calcinosis beginning in early childhood is rare. No treatment is uniformly effective, although Janus kinase ( JAK) inhibitors have emerged as an option for refractory calcinosis.2,4
No takes yet. Share an insight, caveat, or question.
Correia et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: